← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Fibrates
fenofibrate
C10AB05
Forms & Strengths
- Tablet: 48mg, 145mg
- Capsule: 67mg, 134mg, 200mg
- Oral powder: 40mg, 120mg, 140mg
Adult Dosing
- Hyperlipidemia: 48-145mg once daily
- Hypertriglyceridemia: 48-145mg once daily
- Mixed dyslipidemia: 48-145mg once daily
Pediatric Dosing
- Limited data available, not recommended for children under 18 years old
Indications
- Hyperlipidemia
- Hypertriglyceridemia
- Mixed dyslipidemia
- Primary hypercholesterolemia
Mechanism of Action
- Activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha)
- Increases lipolysis and elimination of triglyceride-rich particles
- Decreases triglyceride synthesis in liver
Contraindications
- Severe renal impairment
- Hepatic insufficiency
- Gallbladder disease
- Breastfeeding
Adverse Reactions
- Myopathy
- Rhabdomyolysis
- Increased liver enzymes
- Gastrointestinal disturbance
- Myalgia
Drug Interactions
- CYP2C9 inhibitors (e.g. warfarin)
- HMG-CoA reductase inhibitors (e.g. statins)
- Cyclosporine
- Immunosuppressants
Curated Content: Needs Vetting Before Put to Clinical Use